Brief: Evolva H1 Order Intake At CHF 6.2 Mln

EvoNext Holdings SA

26/08/2020 06:13

Aug 26 (Reuters) - EVOLVA HOLDING SA  EVE.S :
    * H1 RECORD ORDER INTAKE OF CHF 6.2M DRIVEN BY HEALTH
INGREDIENTS,
OF WHICH ONLY CHF 3.8M (+27%) COULD BE REALIZED DUE TO DELAYS AT
CMOS
    * WE REMAIN ON TRACK TO DELIVER ON OUR COMMITMENT TO ACHIEVE
CASH
BREAK-EVEN BY 2023
    * DURING FIRST HALF OF YEAR, COVID-19 NEGATIVELY IMPACTED
MAINLY
F&F SALES AND SOME CMO'S OPERATIONS
    * H1 PRODUCT-RELATED REVENUE INCREASED TO CHF 3.8M FROM CHF
3.0M
(+27%) AS A RESULT OF HIGHER MARKET DEMAND
    * WITH (PARTIAL) EASING OF LOCKDOWN MEASURES, WE ARE
CONFIDENT TO
COMPENSATE THAT SHORTFALL DURING SECOND HALF OF 2020
    * ON A REPORTED BASE, H1 TOTAL REVENUE DECREASED TO CHF 4.0M
FROM
CHF 6.4M (-38%).
    * OUTLOOK 2020: DESPITE A CHALLENGING GLOBAL ENVIRONMENT, WE
EXPECT PRODUCT-RELATED REVENUE TO DOUBLE OVER PRIOR YEAR, AND A
FADING OUT OF R&D REVENUE FOLLOWING COMPLETION OF CONTRACT
WITH BARDA
    * EBITDA LOSS FOR FULL-YEAR IS EXPECTED TO BE ABOVE
PRIOR-YEAR
LEVEL IN 2020
    * EXPECTS GROSS PROFIT ON PRODUCT SALES TO IMPROVE IN SECOND
HALF
OF YEAR.

Source text: https://bit.ly/3b4zKyM
Further company coverage:  EVE.S 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))